SMS Pharmaceuticals Q4 FY26 Results: PAT Rs 21 Cr
- May 22, 2026
- Posted by: Neeraj Pandey
- Category: News
SMS Pharmaceuticals Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 21 crore for the quarter ended March 31, 2026, up 5.0% YoY compared to Rs 20 crore in Q4 FY25. Revenue from operations was Rs 238 crore, down 4.0% YoY. Results are on a Consolidated basis. SMS Pharmaceuticals is a Pharmaceutical APIs company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
SMS Pharmaceuticals Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | Rs 238 crore | Rs 248 crore | -4.0% |
| Gross Profit | Rs 30 crore | Rs 32 crore | -6.0% |
| Net Profit | 21 | 20 | +5.0% |
| Basis | Consolidated | ||
Note: SMS Pharmaceuticals Q4 FY26 results declared May 22, 2026. Verify from BSE/NSE audited filings before investment decisions.
SMS Pharmaceuticals Q4 FY26 Performance Analysis
The SMS Pharmaceuticals Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The company delivered steady performance in line with sector trends. SMS Pharmaceuticals operates in the Pharmaceutical APIs sector, which is supported by India’s GDP growth above 6.5% and domestic demand tailwinds in FY26.
Revenue of Rs 238 crore was down 4.0% YoY. Revenue moderation reflects demand headwinds in the Pharmaceutical APIs segment.
Screen the best stocks on the Univest Screener.
Key Factors Driving SMS Pharmaceuticals Q4 FY26 Results
Revenue Performance
Revenue of Rs 238 crore in SMS Pharmaceuticals Q4 FY26 was down 4.0% YoY. Near-term revenue pressure in SMS Pharmaceuticals Q4 FY26 reflects competitive dynamics and demand moderation in the Pharmaceutical APIs market. The January to March 2026 quarter is the year-end quarter, characterised by strong order execution and fiscal year-end activity across Indian corporates.
Profitability and Margin Analysis
The the business PAT of Rs 21 crore up 5.0% YoY. Stable profitability reflects consistent margin management.
Sector Tailwinds and India Macro Environment
The Pharmaceutical APIs sector saw constructive operating conditions in Q4 FY26. India’s macroeconomic environment, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption, supported demand across sectors. The Reserve Bank of India’s accommodative liquidity stance aided credit conditions. For SMS Pharmaceuticals, these macro and sectoral tailwinds provided a supportive backdrop in the January to March 2026 quarter.
FY27 Outlook
Following the firm results, management commentary on FY27 revenue guidance, margin trajectory, capex plans, and demand pipeline will be the key investor focus areas. The Pharmaceutical APIs sector benefits from India’s long-term growth story including urbanisation, infrastructure investment, and rising middle-class consumption. Consistent growth delivery and margin improvement remain the management’s strategic priorities.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is SMS Pharmaceuticals Q4 FY26 net profit?
Ans. SMS Pharmaceuticals Q4 FY26 PAT of Rs 21 crore, up 5.0% YoY from Rs 20 crore in Q4 FY25. Results declared May 22, 2026, on a Consolidated basis. Verify from BSE/NSE audited filings.
What is SMS Pharmaceuticals Q4 FY26 revenue?
Ans. SMS Pharmaceuticals Q4 FY26 revenue from operations was Rs 238 crore, down 4.0% YoY. Verify complete financials from BSE/NSE filings.
When were SMS Pharmaceuticals Q4 FY26 results declared?
Ans. SMS Pharmaceuticals Q4 FY26 results were declared on May 22, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.
Is SMS Pharmaceuticals a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before investing in SMS Pharmaceuticals.
